Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
Open Access
- 16 June 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (12) , 2653
Abstract
Reports of the prevalence of antibodies to infliximab (anti-drug antibodies, ADA) are inconsistent due in part to the various assay formats used to monitor immunogenicity in the clinic and under clinical trial settings. This study aimed to determine the frequency of ADA in patients with inflammatory bowel disease (IBD) during induction and maintenance therapy with biosimilar infliximab (CT-P13) using the ELISA (enzyme-linked immunosorbent assay) method. In this prospective single-center study, we analyzed the incidence of ADA and the relationship between the presence of ADA and the following variables: gender, type of disease, immunosuppressive therapy used, and duration of treatment. A total of 84 patients with IBD received CT-P13 and were followed up for an average of 7 months. We found ADA in 50% of the patients with undetectable levels of the drug. The percentage of persons with antibodies detected during induction treatment was 11.3% compared to 9.6% during maintenance therapy. The analysis showed no relationship between response to treatment and antibody titers (p = 0.381). The study showed a statistically significant relationship between undetectable levels of CT-P13 and the presence of ADA at week 6 of therapy (i.e., ADA were detected in all the patients with undetectable levels of CT-P13). Patients with IBD and undetectable levels of CT-P13 before administration of the third induction dose were at high risk of the presence of anti-drug antibodies as well as primary non-response.Keywords
This publication has 35 references indexed in Scilit:
- Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapiesClinical Immunology, 2019
- Immunogenicity of biologics in inflammatory bowel diseaseTherapeutic Advances in Gastroenterology, 2018
- Final Results on Efficacy and Safety of Biosimilar Infliximab after One-Year: Results from a Prospective Nationwide CohortGastroenterology, 2017
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An UpdateJournal of Crohn's and Colitis, 2016
- Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsTherapeutic Advances in Gastroenterology, 2016
- Loss of Response to Anti-TNFs: Definition, Epidemiology, and ManagementClinical and Translational Gastroenterology, 2016
- Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single centerExpert Opinion on Biological Therapy, 2015
- Optimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and healthGut, 2011
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003